Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 682-692 , May 2011

CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory Cells

  • Jiehua Zhou

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Asad Bashey

      Affiliations

    • Blood and Marrow Transplant and Leukemia Program, Northside Hospital, Atlanta, Georgia
    • ,
  • Ruikun Zhong

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Sue Corringham

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Karen Messer

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Minya Pu

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Wenxue Ma

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Theresa Chut

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • ,
  • Robert Soiffer

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Rachel C. Mitrovich

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Israel Lowy

      Affiliations

    • Medarex Inc, Princeton, New Jersey
    • ,
  • Edward D. Ball

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California
    • Corresponding Author InformationCorrespondence and reprint requests: Dr. Edward D. Ball, Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093.

Received 18 March 2010 ,Accepted 5 August 2010.

References 

  1. Mielcarek M, Storer BE, Flowers ME, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1160–1168
  2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296
  3. Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285–1294
  4. Zhang L, Zhao Y. The regulation of Foxp3 expression in regulatory CD4+CD25+ T cells: multiple pathways on the road. J Cell Physiol. 2007;211:590–597
  5. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24:65–97
  6. Corthay A. How do regulatory T cells work?. Scand J Immunol. 2009;70:326–336
  7. Viguier M, Lemaitre F, Verola O, et al. Foxp3-expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444–1453
  8. Cai S, Cao X, Hassan A, et al. Granzyme B is not required for regulatory T cell–mediated suppression of graft-versus-host disease. Blood. 2010;115:1669–1677
  9. Kosmaczewska A, Ciszak L, Potoczek S, et al. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp. 2008;56:181–191
  10. Yamaguchi T, Sakaguchi S. Regulator T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115–123
  11. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243–265
  12. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804–811
  13. Sinicrope FA, Rego RL, Ansell SM, et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009;137:1270–1279
  14. Review Weber J. Anti–CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864–872
  15. Keilholz U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother. 2008;31:431–439
  16. Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MXD-010): a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009;9:231–241
  17. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen 4 blockade in advanced melonoma. Melanoma Res. 2010;20:1–10
  18. Sun J, Schiffman J, Raghunath A, et al. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti–CTLA-4 therapy. Cancer Immun. 2008;8:9–13
  19. Kavanagh B, O’Brien S, Lee D, et al. CTLA-4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008;112:1175–1183
  20. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175:7746–7754
  21. Fong L, Kwek SS, O’Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009;69:609–615
  22. Fevery S, Billiau AD, Sprangers B, et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia. 2007;21:1451–1459
  23. May KF, Roychowdhury S, Bhatt D, et al. Anti-human CTLA-4 monoclonal antibody promotes expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood. 2005;105:1114–1120
  24. Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006;177:4376–4383
  25. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108:1291–1297
  26. Zorn E. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol. 2006;16:150–159
  27. Clark FJ, Gregg R, Piper K, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood. 2004;103:2410–2416
  28. Miura Y, Thobum CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104:2187–2193
  29. Rezvani AR, Storb RF. Separation of graft-vs-tumor effects from graft-vs-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun. 2008;30:172–179
  30. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1581–1588
  31. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–1253
  32. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–5598
  33. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075–1081
  34. Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950–5956
  35. Atanackovic D, Cao Y, Luetkens T, et al. CD4+CD25+FOXP3+ T regulatory cells reconstitution and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica. 2008;93:423–430
  36. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease. Blood. 2007;110:1689–1697
  37. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melonoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–164
  38. Allen SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells dose not suppress proliferation or cytokine production. Int Immunol. 2007;19:345–354
  39. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen 4. J Clin Oncol. 2005;23:6043–6053
  40. Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2010;In Press
  41. Wang XB, Zheng CY, Giscombe R, et al. Regulation of surface and intracellular CTLA-4 on human peripheral T cells. Scand J Immunol. 2001;54:453–458
  42. Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer treatment. Expert Opin Biol Ther. 2009;9:231–241
  43. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717–1725

 Financial disclosure: See Acknowledgments on page 691.

PII: S1083-8791(10)00344-7

doi: 10.1016/j.bbmt.2010.08.005

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 682-692 , May 2011

Article Tools

* Image Usage & Resolution